<DOC>
	<DOCNO>NCT00600249</DOCNO>
	<brief_summary>The purpose study assess pathological response rate operable breast cancer patient treat neoadjuvant combination `` Taxotere-Erbitux '' .</brief_summary>
	<brief_title>Assessment Efficacy Neoadjuvant Combination : `` Chemotherapy-targeted Therapy '' Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>§ Age &gt; equal 18 years.§ Performance status inferior equal 1 ( WHO criteria ) Histologically prove breast cancer , non metastatic , clinical tumor diameter &gt; equal 2 cm . HR negative HER 2 negative . Clinical stage II IIIa . Non prior treat patient either surgery , radiotherapy , hormonotherapy chemotherapy.§ Adequate hematological , renal hepatic function : neutrophil &gt; 2.109 /L , platelet &gt; 100.109 /L , Hb &gt; 10 g/dL , normal bilirubin , ASAT ALAT inferior equal 2,5 ULN ( upper normal limit ) , alkaline phosphatase £ 2,5 ULN , creatinine &lt; 140 µmol/L creatinine clearance &gt; 60 mL/min.§ Written inform consent§ Affiliation social security system ( profit mode ) accord term ' law August 9 , 2004 . Male patient . Pregnant lactate woman childbearing potential efficacy contraception . Other breast cancer form particularly inflammatory form and/or negliged ( T4b T4d ) .§ Non measurable tumor . Prior surgery primary axillary dissection . Prior treatment new breast cancer . Under guardianship patient Patient antecedent second cancer , except situ uterine carcinoma basocellular cutaneous cancer consider definitively cure . Patient associate pathology consider incompatible study.§ Cardiac , renal , medullar , respiratory hepatic insufficiency . Significant neurological psychiatric troubles.§ Symptomatic evolutive trouble CNS metastasis . Peripheral neuropathy &gt; grade 2 NCICTC ( version 3.0 ) Previous allergy polysorbate 80 . Concomitant treatment drug test clinical trial , participation another clinical study , last thirty day prior chemotherapy . Patients non stable follow 6 month leave great distance participate center .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Breast cancer .</keyword>
	<keyword>Triple negative .</keyword>
	<keyword>Neoadjuvant chemotherapy .</keyword>
	<keyword>Targeted therapy .</keyword>
</DOC>